Targeting insulin-like growth factor pathways.

Abstract:

:Some cancer cells depend on the function of specific molecules for their growth, survival, and metastatic potential. Targeting of these critical molecules has arguably been the best therapy for cancer as demonstrated by the success of tamoxifen and trastuzumab in breast cancer. This review will evaluate the type I IGF receptor (IGF-IR) as a potential target for cancer therapy. As new drugs come forward targeting this receptor system, several issues will need to be addressed in the early clinical trials using these agents.

journal_name

Br J Cancer

authors

Yee D

doi

10.1038/sj.bjc.6602963

subject

Has Abstract

pub_date

2006-02-27 00:00:00

pages

465-8

issue

4

eissn

0007-0920

issn

1532-1827

pii

6602963

journal_volume

94

pub_type

杂志文章,评审
  • Phase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitor.

    abstract:BACKGROUND:Tumoural interstitial hypertension, possibly modulated by platelet-derived and vascular endothelial growth factor receptors (PDGFR and VEGFR), may mediate resistance to chemotherapy. METHODS:Forty-eight patients with advanced solid tumours received oral PDGFR inhibitor CP-868,596 (60-100 mg twice daily (BID...

    journal_title:British journal of cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1038/sj.bjc.6605941

    authors: Michael M,Vlahovic G,Khamly K,Pierce KJ,Guo F,Olszanski AJ

    更新日期:2010-11-09 00:00:00

  • Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers.

    abstract::Insulin-like growth factors (IGFs) I and II are implicated in progression of various tumours including colorectal carcinomas. To interfere with the production of IGFs, we treated male nude mice bearing xenografts of HT-29 human colon cancer with various potent growth hormone-releasing hormone (GH-RH) antagonists. Twic...

    journal_title:British journal of cancer

    pub_type: 杂志文章

    doi:10.1054/bjoc.2000.1223

    authors: Szepeshazi K,Schally AV,Groot K,Armatis P,Halmos G,Herbert F,Szende B,Varga JL,Zarandi M

    更新日期:2000-05-01 00:00:00

  • Comparison of tumour susceptibility among various organs of foetal, young and adult ICR/Jcl mice.

    abstract::Urethane was found to be uniformly distributed in all the major organs of foetal, young and adult ICR/Jcl mice and then to disappear rapidly as measured by the incorporation of urethane-carbonyl-14C, thus permitting the accurate comparison of tumour susceptibility of cells in various organs of mice at different ages. ...

    journal_title:British journal of cancer

    pub_type: 杂志文章

    doi:10.1038/bjc.1976.83

    authors: Nomura T

    更新日期:1976-05-01 00:00:00

  • Differential expression of myc, max and RB1 genes in human gliomas and glioma cell lines.

    abstract::Deregulated expression of myc proto-oncogenes is implicated in several human neoplasias. We analysed the expression of c-myc, N-myc, L-myc, max and RB1 mRNAs in a panel of human gliomas and glioma cell lines and compared the findings with normal neural cells. The max and RB1 genes were included in the study because th...

    journal_title:British journal of cancer

    pub_type: 杂志文章

    doi:10.1038/bjc.1994.3

    authors: Hirvonen HE,Salonen R,Sandberg MM,Vuorio E,Västrik I,Kotilainen E,Kalimo H

    更新日期:1994-01-01 00:00:00

  • Upregulation and differential expression of matrilysin (MMP-7) and metalloelastase (MMP-12) and their inhibitors TIMP-1 and TIMP-3 in Barrett's oesophageal adenocarcinoma.

    abstract::Oesophageal adenocarcinoma is believed to arise from metaplastic mucosa in the distal oesophagus, a condition also known as Barrett's oesophagus (BE). BE develops as a result of injury caused by refluxing gastric and duodenal contents and is associated with increased risk of malignant transformation. Matrix metallopro...

    journal_title:British journal of cancer

    pub_type: 杂志文章

    doi:10.1054/bjoc.2001.1929

    authors: Salmela MT,Karjalainen-Lindsberg ML,Puolakkainen P,Saarialho-Kere U

    更新日期:2001-08-03 00:00:00

  • The response of leptin, interleukin-6 and fat oxidation to feeding in weight-losing patients with pancreatic cancer.

    abstract::At baseline, weight-losing pancreatic cancer patients (n=7) had lower leptin (P<0.05) but higher cortisol, interleukin-6, resting energy expenditure and fat oxidation than healthy subjects (n=6, P<0.05). Over a 4 h feeding period, the areas under the curve for glucose, cortisol and interleukin-6 were greater (P<0.05),...

    journal_title:British journal of cancer

    pub_type: 杂志文章

    doi:10.1038/sj.bjc.6601712

    authors: Barber MD,McMillan DC,Wallace AM,Ross JA,Preston T,Fearon KC

    更新日期:2004-03-22 00:00:00

  • MutSbeta exceeds MutSalpha in dinucleotide loop repair.

    abstract:BACKGROUND:The target substrates of DNA mismatch recognising factors MutSalpha (MSH2+MSH6) and MutSbeta (MSH2+MSH3) have already been widely researched. However, the extent of their functional redundancy and clinical substance remains unclear. Mismatch repair (MMR)-deficient tumours are strongly associated with microsa...

    journal_title:British journal of cancer

    pub_type: 杂志文章

    doi:10.1038/sj.bjc.6605531

    authors: Kantelinen J,Kansikas M,Korhonen MK,Ollila S,Heinimann K,Kariola R,Nyström M

    更新日期:2010-03-16 00:00:00

  • Lack of correlation between in vivo rejection of syngeneic fibrosarcomas and in vitro non-specific macrophage cytotoxicity.

    abstract::Two transplantable, highly immunogenic syngeneic C57BL fibrosarcomas, FS1 and FS6, were shown to have tumour-specific rejection antigens, as shown by excision of the primary tumours and i.p. or i.m. injection of graded doses of the specific and unrelated tumour cells. I.p. challenge with tumour cells induced a large a...

    journal_title:British journal of cancer

    pub_type: 杂志文章

    doi:10.1038/bjc.1978.253

    authors: Evans R,Booth CG,Spencer F

    更新日期:1978-11-01 00:00:00

  • Tumour prothymosin alpha content, a potential prognostic marker for primary breast cancer.

    abstract::In a previous report we suggested that the estimation of prothymosin alpha (PTA) levels in primary breast tumours might be used to identify breast cancer patients at high risk for distant metastasis (Dominguez F et al (1993) Eur J Cancer 29A: 893-897). Here the role of tumour PTA levels as predictor was investigated w...

    journal_title:British journal of cancer

    pub_type: 杂志文章

    doi:10.1054/bjoc.1999.0968

    authors: Magdalena C,Dominguez F,Loidi L,Puente JL

    更新日期:2000-02-01 00:00:00

  • Characterisation of fibronectin-mediated FAK signalling pathways in lung cancer cell migration and invasion.

    abstract:BACKGROUND:Focal adhesion kinase (FAK) is overexpressed in a variety of cancers, such as breast, colon, prostate, ovary, and lung cancers. However, the mechanism by which extracellular matrix fibronectin stimulates lung cancer cell migration and invasion through FAK remains to be investigated. METHODS:The signalling p...

    journal_title:British journal of cancer

    pub_type: 杂志文章

    doi:10.1038/sj.bjc.6605154

    authors: Meng XN,Jin Y,Yu Y,Bai J,Liu GY,Zhu J,Zhao YZ,Wang Z,Chen F,Lee KY,Fu SB

    更新日期:2009-07-21 00:00:00

  • Recognition and killing of tumour cells expressing heat shock protein 65 kD with immunotoxins containing saporin.

    abstract::The expression of heat shock proteins (HSP) of the 65 kD family (groEL) has been observed by flow cytometry using murine monoclonal antibody (MoAb) anti-HSP 65 kD (ML30) on the surface of B (Daudi) or T (H9) lymphoma cells, on a monocyte cell line (U937) and also on a primary culture of a human pancreatic carcinoma (H...

    journal_title:British journal of cancer

    pub_type: 杂志文章

    doi:10.1038/bjc.1992.291

    authors: Poccia F,Piselli P,Di Cesare S,Bach S,Colizzi V,Mattei M,Bolognesi A,Stirpe F

    更新日期:1992-09-01 00:00:00

  • EPIC: an effective low toxicity regimen for relapsing lymphoma.

    abstract::We have treated 40 patients was relapsed or resistant lymphoma with the combination of Etoposide, Prednisolone, Ifosfamide and Cisplatin (EPIC). Complete response was obtained in 11 patients (28%) with an overall response of 58%. The presence of bulky disease (P < 0.005), elevated LDH serum levels (P < 0.005), respons...

    journal_title:British journal of cancer

    pub_type: 临床试验,杂志文章

    doi:10.1038/bjc.1993.393

    authors: Hickish T,Roldan A,Cunningham D,Mansi J,Ashley S,Nicolson V,Gore ME,Catovsky D,Smith IE

    更新日期:1993-09-01 00:00:00

  • Phase II multi-institutional prospective randomised trial comparing S-1+paclitaxel with S-1+cisplatin in patients with unresectable and/or recurrent advanced gastric cancer.

    abstract:BACKGROUND:A combination of S-1 and cisplatin has been shown to be effective with acceptable safety for the first-line treatment of far-advanced gastric cancer in Japan. This is the first randomised phase II trial to compare S-1+paclitaxel with S-1+cisplatin in this setting. METHODS:Patients with unresectable and/or r...

    journal_title:British journal of cancer

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1038/bjc.2012.222

    authors: Mochiki E,Ogata K,Ohno T,Toyomasu Y,Haga N,Fukai Y,Aihara R,Ando H,Uchida N,Asao T,Kuwano H,North Kanto Gastric Cancer Study Group.

    更新日期:2012-06-26 00:00:00

  • Hepatic arterial floxuridine as second-line treatment for systemic fluorouracil-resistant colorectal liver metastases.

    abstract::Hepatic arterial floxuridine (HAI) in 35 patients with systemic fluorouracil/folinic acid-resistant colorectal liver metastases achieved a 14% partial response and 26% disease stabilization rate, with a median response duration of 7 months from onset of HAI. ...

    journal_title:British journal of cancer

    pub_type: 临床试验,杂志文章

    doi:10.1038/bjc.1998.627

    authors: Fordy C,Glover C,Davies MM,Allen-Mersh TG

    更新日期:1998-10-01 00:00:00

  • Long-term health outcomes in a British cohort of breast, colorectal and prostate cancer survivors: a database study.

    abstract:BACKGROUND:The community-based incidence of cancer treatment-related long-term consequences is uncertain. We sought to establish the burden of health outcomes that have been associated with treatment among British long-term cancer survivors. METHODS:We identified 26,213 adults from the General Practice Research Databa...

    journal_title:British journal of cancer

    pub_type: 杂志文章

    doi:10.1038/bjc.2011.420

    authors: Khan NF,Mant D,Carpenter L,Forman D,Rose PW

    更新日期:2011-11-08 00:00:00

  • Nine-factor-based immunohistochemistry classifier predicts recurrence for early-stage hepatocellular carcinoma after curative resection.

    abstract:BACKGROUND:Immunoscore have shown a promising prognostic value in many cancers. We aimed to establish and validate an immune classifier to predict survival after curative resection of hepatocellular carcinoma (HCC) patients who have undergone curative resection. METHODS:The immunohistochemistry (IHC) classifier assay ...

    journal_title:British journal of cancer

    pub_type: 杂志文章

    doi:10.1038/s41416-020-0864-0

    authors: Liu WR,Tian MX,Tang Z,Fang Y,Zhou YF,Song SS,Jiang XF,Wang H,Tao CY,Zhou PY,Qu WF,Ding ZB,Peng YF,Zhou J,Fan J,Shi YH

    更新日期:2020-07-01 00:00:00

  • Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumours.

    abstract:BACKGROUND:Tumours are responsive to temozolomide (TMZ) if they are deficient in O(6)-methylguanine-DNA methyltransferase (MGMT), and mismatch repair (MMR) proficient. METHODS:The effect of TMZ on medulloblastoma (MB) cell killing was analysed with clonogenic survival assays. Expression of DNA repair genes and enzymes...

    journal_title:British journal of cancer

    pub_type: 杂志文章

    doi:10.1038/bjc.2012.403

    authors: von Bueren AO,Bacolod MD,Hagel C,Heinimann K,Fedier A,Kordes U,Pietsch T,Koster J,Grotzer MA,Friedman HS,Marra G,Kool M,Rutkowski S

    更新日期:2012-10-09 00:00:00

  • Serum beta-carotene and subsequent risk of cancer: results from the BUPA Study.

    abstract::In the BUPA Study, a prospective study of 22,000 men attending a screening centre in London, serum samples were collected and stored. The concentration of beta-carotene was measured in the stored serum samples from 271 men who were subsequently notified as having cancer and from 533 unaffected controls, matched for ag...

    journal_title:British journal of cancer

    pub_type: 杂志文章

    doi:10.1038/bjc.1988.97

    authors: Wald NJ,Thompson SG,Densem JW,Boreham J,Bailey A

    更新日期:1988-04-01 00:00:00

  • MSH6 missense mutations are often associated with no or low cancer susceptibility.

    abstract::Mismatch repair (MMR) deficiency in tumours from patients with the hereditary nonpolyposis colorectal cancer (HNPCC) syndrome is mainly caused by mutations in the MLH1, MSH2, and MSH6 genes. A major challenge in the clinical management of patients with suspected HNPCC is the frequent occurrence of missense mutations i...

    journal_title:British journal of cancer

    pub_type: 杂志文章

    doi:10.1038/sj.bjc.6602129

    authors: Kariola R,Hampel H,Frankel WL,Raevaara TE,de la Chapelle A,Nyström-Lahti M

    更新日期:2004-10-04 00:00:00

  • Mechanistic modelling of dynamic MRI data predicts that tumour heterogeneity decreases therapeutic response.

    abstract:BACKGROUND:Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) contains crucial information about tumour heterogeneity and the transport limitations that reduce drug efficacy. Mathematical modelling of drug delivery and cellular responsiveness based on underutilised DCE-MRI data has the unique potential to p...

    journal_title:British journal of cancer

    pub_type: 杂志文章

    doi:10.1038/sj.bjc.6605773

    authors: Venkatasubramanian R,Arenas RB,Henson MA,Forbes NS

    更新日期:2010-08-10 00:00:00

  • Phase II study of lonidamine in metastatic breast cancer.

    abstract::Thirty patients with previously treated metastatic breast cancer were entered in a phase II study with oral lonidamine. Twenty-eight patients are evaluable for toxicity and 25 for response. A partial remission was obtained in four patients (16%) and disease stability in 11 (44%): 10 patients progressed (40%). Toxicity...

    journal_title:British journal of cancer

    pub_type: 杂志文章

    doi:10.1038/bjc.1989.51

    authors: Pronzato P,Amoroso D,Bertelli G,Conte PF,Cusimano MP,Ciottoli GB,Gulisano M,Lionetto R,Rosso R

    更新日期:1989-02-01 00:00:00

  • The current treatment landscape in the UK for stage III NSCLC.

    abstract::For stage III non-small cell lung cancer (NSCLC), approximately a third of patients survive up to 5 years, with decreasing 5-year survival rates for stage IIIB and stage IIIC disease. Although curable, stage III NSCLC encompasses a diverse range of disease presentation, with an equally complex range of multi-modal tre...

    journal_title:British journal of cancer

    pub_type: 杂志文章,评审

    doi:10.1038/s41416-020-01069-z

    authors: Evison M,AstraZeneca UK Limited.

    更新日期:2020-12-01 00:00:00

  • K20 and ICO-10 monoclonal antibodies (gp120/200; Thy-1): immunophenotyping of human solid tumours.

    abstract::Solid tumour cells were shown to express VLA-beta and Thy-1 antigens. For identification of these molecules two monoclonal antibodies, K-20 and ICO-10, characterised in detail previously, were used. Four groups of solid tumours have been identified according to their immunophenotype: VLA-beta+ and Thy-1-; VLA-beta+ an...

    journal_title:British journal of cancer

    pub_type: 杂志文章

    doi:10.1038/bjc.1990.39

    authors: Kadagidze ZG,Tupitsyn NN,Baryshnikov AJ,Kadyrov KP,Blinov VM,Bernard A,Amiot M,Boumsell L

    更新日期:1990-02-01 00:00:00

  • Patient-derived explants (PDEs) as a powerful preclinical platform for anti-cancer drug and biomarker discovery.

    abstract::Preclinical models that can accurately predict outcomes in the clinic are much sought after in the field of cancer drug discovery and development. Existing models such as organoids and patient-derived xenografts have many advantages, but they suffer from the drawback of not contextually preserving human tumour archite...

    journal_title:British journal of cancer

    pub_type: 杂志文章,评审

    doi:10.1038/s41416-019-0672-6

    authors: Powley IR,Patel M,Miles G,Pringle H,Howells L,Thomas A,Kettleborough C,Bryans J,Hammonds T,MacFarlane M,Pritchard C

    更新日期:2020-03-01 00:00:00

  • GEIS-21: a multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: a report from the Spanish sarcoma group (GEIS).

    abstract:BACKGROUND:First Spanish trial of Ewing sarcoma (ES) including adults and children with the aim to test the efficacy of Gemcitabine and Docetaxel (G/D) in newly diagnosed high-risk (HR) patients. METHODS:This was a prospective, multicentric, non-randomised, open study for patients ⩽40 years with newly diagnosed ES. HR...

    journal_title:British journal of cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1038/bjc.2017.252

    authors: Mora J,Castañeda A,Perez-Jaume S,Lopez-Pousa A,Maradiegue E,Valverde C,Martin-Broto J,Garcia Del Muro X,Cruz O,Cruz J,Martinez-Trufero J,Maurel J,Vaz MA,de Alava E,de Torres C

    更新日期:2017-09-05 00:00:00

  • Phase 2 study of combination SPI-1620 with docetaxel as second-line advanced biliary tract cancer treatment.

    abstract:BACKGROUND:This multicentre, open-label study evaluated the efficacy and safety of SPI-1620, an analogue of endothelin-1, administered in combination with docetaxel as second-line treatment for patients with advanced biliary tract cancer (ABTC). METHODS:Eligible patients received continuous cycles of combination thera...

    journal_title:British journal of cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1038/bjc.2017.160

    authors: Kim R,Chiorean EG,Amin M,Rocha-Lima CMS,Gandhi J,Harris WP,Song T,Portnoy D

    更新日期:2017-07-11 00:00:00

  • Cost-effectivenes of paclitaxel plus cisplatin in advanced non-small-cell lung cancer.

    abstract::The aim of this study was to assess the cost-effectiveness of combination chemotherapy with paclitaxel/cisplatin, compared with standard etoposide/cisplatin in patients with advanced non-small cell lung cancer (NSCLC). We obtained the primary survival and resource utilization data from a large three-arm randomized tri...

    journal_title:British journal of cancer

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1038/sj.bjc.6690426

    authors: Earle CC,Evans WK

    更新日期:1999-05-01 00:00:00

  • Specific roles for the PI3K and the MEK-ERK pathway in IGF-1-stimulated chemotaxis, VEGF secretion and proliferation of multiple myeloma cells: study in the 5T33MM model.

    abstract::Insulin-like growth factor-1 (IGF-1) has been described as an important factor in proliferation, cell survival and migration of multiple myeloma (MM) cells. Angiogenesis correlates with development and prognosis of the MM disease. Vascular endothelial growth factor (VEGF) is one of the prominent factors involved in th...

    journal_title:British journal of cancer

    pub_type: 杂志文章

    doi:10.1038/sj.bjc.6601613

    authors: Menu E,Kooijman R,Van Valckenborgh E,Asosingh K,Bakkus M,Van Camp B,Vanderkerken K

    更新日期:2004-03-08 00:00:00

  • Adiposity and risks of colorectal and small intestine cancer in Chinese adults: a prospective study of 0.5 million people.

    abstract:BACKGROUND:Uncertainty remains about the associations of adiposity with intestinal cancer in China and by its anatomical subtype. METHODS:The prospective China Kadoorie Biobank recorded 3024 incident cases of colorectal (CRC) and 143 cases of small intestine (SIC) cancer during a 10-year follow-up among 509 568 partic...

    journal_title:British journal of cancer

    pub_type: 杂志文章

    doi:10.1038/s41416-018-0124-8

    authors: Pang Y,Kartsonaki C,Guo Y,Chen Y,Yang L,Bian Z,Bragg F,Millwood IY,Mao E,Li Y,Shi L,Chen J,Li L,Holmes MV,Chen Z

    更新日期:2018-07-01 00:00:00

  • High expression of tumour-associated trypsin inhibitor correlates with liver metastasis and poor prognosis in colorectal cancer.

    abstract::Increased expression of tumour-associated trypsin inhibitor (TATI) in tumour tissue and/or serum has been associated with poor survival in various cancer forms. Moreover, a proinvasive function of TATI has been shown in colon cancer cell lines. In this study, we have examined the prognostic significance of tumour-spec...

    journal_title:British journal of cancer

    pub_type: 杂志文章

    doi:10.1038/sj.bjc.6605047

    authors: Gaber A,Johansson M,Stenman UH,Hotakainen K,Pontén F,Glimelius B,Bjartell A,Jirström K,Birgisson H

    更新日期:2009-05-19 00:00:00